Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Compass Pathways PLC (ADR) - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CMPS
Nasdaq
8731
https://compasspathways.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Compass Pathways PLC (ADR)
Compass Pathways to participate in upcoming 23rd Annual Needham Virtual Healthcare Conference
- Apr 1st, 2024 8:01 pm
20 Most Depressed Countries in Asia
- Mar 31st, 2024 9:47 pm
Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors
- Mar 28th, 2024 12:00 pm
10 Alternatives to Antidepressant Medications
- Mar 10th, 2024 2:00 pm
15 Highest Paying Jobs with a Psychology Degree
- Mar 5th, 2024 2:59 pm
20 Countries with Most Antidepressant Users in the World
- Mar 5th, 2024 1:52 pm
COMPASS Pathways plc (NASDAQ:CMPS) Q4 2023 Earnings Call Transcript
- Mar 1st, 2024 2:08 pm
Compass Pathways Plc (CMPS) Q4 2023 Earnings Call Transcript
- Feb 29th, 2024 8:30 pm
Compass Pathways PLC Reports Increased Annual Net Loss Amid Clinical Advancements
- Feb 29th, 2024 12:34 pm
Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights
- Feb 29th, 2024 12:00 pm
Penny Power Players: 3 Stocks to Watch in the Microcap Arena
- Feb 27th, 2024 5:33 pm
Compass Pathways to participate in upcoming TD Cowen investor conference
- Feb 26th, 2024 9:01 pm
Compass Pathways to announce fourth quarter and year-end 2023 financial results on February 29, 2024
- Feb 22nd, 2024 9:01 pm
Mental Health Mavericks: 3 Stocks Changing the Game
- Feb 21st, 2024 8:06 pm
Wall Street Says Compass Pathways Could Rise 307%. Here's How It Could Actually Happen.
- Feb 19th, 2024 12:00 pm
As investors pile into psychedelics, idealism gives way to pharma economics
- Feb 2nd, 2024 9:27 pm
Compass Pathways to participate in upcoming Oppenheimer investor conference
- Jan 31st, 2024 9:01 pm
Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approved
- Jan 16th, 2024 1:00 pm
Therapy’s New Frontier: 3 Psychedelic Stocks for the Mental Health Revolution
- Jan 9th, 2024 6:56 pm
3 Big New Catalysts for Psychedelics Stocks in 2024
- Jan 8th, 2024 4:47 pm
Scroll